Natural killer-based cell therapy developer Artiva Biotherapeutics has announced an IPO to raise to USD 100 million. This comes after an earlier IPO attempt in 2021 that was withdrawn in 2022. The company will start trading on the Nasdaq under the symbol "ARTV."
Although the specific use of the funds was undisclosed, the company is currently conducting Phase I/Ib trials for its lead candidate, AlloNK, for autoimmune diseases such as lupus nephritis and expects to reveal the initial data of the trials in 2025.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.